411 related articles for article (PubMed ID: 17390306)
1. Practical usage of O'Brien's OLS and GLS statistics in clinical trials.
Dallow NS; Leonov SL; Roger JH
Pharm Stat; 2008; 7(1):53-68. PubMed ID: 17390306
[TBL] [Abstract][Full Text] [Related]
2. Group sequential t-test for clinical trials with small sample sizes across stages.
Shao J; Feng H
Contemp Clin Trials; 2007 Sep; 28(5):563-71. PubMed ID: 17434814
[TBL] [Abstract][Full Text] [Related]
3. The appropriateness of the Wilcoxon test in ordinal data.
Hilton JF
Stat Med; 1996 Mar; 15(6):631-45. PubMed ID: 8731005
[TBL] [Abstract][Full Text] [Related]
4. Stratified tests, stratified slopes, and random effects models for clinical trials with missing data.
Dawson JD; Han SH
J Biopharm Stat; 2000 Nov; 10(4):447-55. PubMed ID: 11104386
[TBL] [Abstract][Full Text] [Related]
5. Uncertainties beyond statistics in Monte Carlo simulations.
Hughes HG
Radiat Prot Dosimetry; 2007; 126(1-4):45-51. PubMed ID: 17766264
[TBL] [Abstract][Full Text] [Related]
6. Two new covariate adjustment methods for non-inferiority assessment of binary clinical trials data.
Hou Y; Ding V; Li K; Zhou XH
J Biopharm Stat; 2011 Jan; 21(1):77-93. PubMed ID: 21191856
[TBL] [Abstract][Full Text] [Related]
7. Power analyses for correlations from clustered study designs.
Tu XM; Kowalski J; Crits-Christoph P; Gallop R
Stat Med; 2006 Aug; 25(15):2587-606. PubMed ID: 16025545
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the statistical power for multiple tests: a case study.
Yeo A; Qu Y
Pharm Stat; 2009; 8(1):5-11. PubMed ID: 18381588
[TBL] [Abstract][Full Text] [Related]
9. [Using CTS and PK-PD models to predict the effect of uncertainty about population parameters on clinical trial power].
Zhu L; Shi X; Liu Y
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Feb; 26(1):42-6, 62. PubMed ID: 19334551
[TBL] [Abstract][Full Text] [Related]
10. Sample size and the probability of a successful trial.
Chuang-Stein C
Pharm Stat; 2006; 5(4):305-9. PubMed ID: 17128428
[TBL] [Abstract][Full Text] [Related]
11. Diagnosing model diagnostics.
Karlsson MO; Savic RM
Clin Pharmacol Ther; 2007 Jul; 82(1):17-20. PubMed ID: 17571070
[TBL] [Abstract][Full Text] [Related]
12. Detecting data fabrication in clinical trials from cluster analysis perspective.
Wu X; Carlsson M
Pharm Stat; 2011; 10(3):257-64. PubMed ID: 20936626
[TBL] [Abstract][Full Text] [Related]
13. The effect of trial size on statistical power.
Bates BT; Dufek JS; Davis HP
Med Sci Sports Exerc; 1992 Sep; 24(9):1059-65. PubMed ID: 1406191
[TBL] [Abstract][Full Text] [Related]
14. Sample size calculation for the van Elteren test adjusting for ties.
Zhao YD; Rahardja D; Mei Y
J Biopharm Stat; 2008; 18(6):1112-9. PubMed ID: 18991111
[TBL] [Abstract][Full Text] [Related]
15. Wilcoxon-Mann-Whitney test: stratify or not?
Qu Y; Zhao YD; Rahardja D
J Biopharm Stat; 2008; 18(6):1103-11. PubMed ID: 18991110
[TBL] [Abstract][Full Text] [Related]
16. [Analysis and importance of statistical power and sample size in empirical scientific research].
Klimek KM
Wiad Lek; 2008; 61(7-9):211-5. PubMed ID: 19172834
[TBL] [Abstract][Full Text] [Related]
17. Statistical power analysis for growth curve models using SAS.
Zhang Z; Wang L
Behav Res Methods; 2009 Nov; 41(4):1083-94. PubMed ID: 19897816
[TBL] [Abstract][Full Text] [Related]
18. Tests for inter-subject and total variabilities under crossover designs.
Lee Y; Shao J; Chow SC; Wang H
J Biopharm Stat; 2002 Nov; 12(4):503-34. PubMed ID: 12477072
[TBL] [Abstract][Full Text] [Related]
19. Monte Carlo simulation of OLS and linear mixed model inference of phenotypic effects on gene expression.
Walker JA
PeerJ; 2016; 4():e2575. PubMed ID: 27761350
[TBL] [Abstract][Full Text] [Related]
20. A general approach for sample size and statistical power calculations assessing of interventions using a mixture model in the presence of detection limits.
Nie L; Chu H; Cole SR
Contemp Clin Trials; 2006 Oct; 27(5):483-91. PubMed ID: 16769254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
